Addex Therapeutics (ADXN)
NASDAQ:ADXN
Want to see ADXN full AI Analyst Report?
ADXN Stock Chart & Stats
$8.23
$0.23(2.80%)
At close: 4:00 PM EST
$8.23
$0.23(2.80%)
Day’s Range― - ―
52-Week Range$5.41 - $12.05
Previous CloseN/A
Volume26.36K
Average Volume (3M)16.10K
Market Cap
$6.78M
Enterprise Value$5.38M
Total Cash (Recent Filing)$1.64M
Total Debt (Recent Filing)$34.73K
Price to Earnings (P/E)―
Beta0.66
Next Earnings
Jun 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.10
Shares Outstanding1,822,121
10 Day Avg. Volume4,441
30 Day Avg. Volume16,099
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.20
Price to Sales (P/S)191.02
P/FCF Ratio-2.76
Enterprise Value/Market Cap0.79
Enterprise Value/Revenue81.14
Enterprise Value/Gross Profit-32.02
Enterprise Value/Ebitda-0.79
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-5.98
Revenue Forecast (FY)$1.79M
Bulls Say, Bears Say
Bulls Say
Allosteric Platform FocusAddex’s proprietary allosteric modulation platform and focus on metabotropic glutamate receptors create a durable R&D advantage: platform approaches can yield multiple drug candidates, support partnering/licensing strategies, and spread discovery risk across programs over the medium term.
Conservative Balance Sheet LeverageExtremely low debt provides financial flexibility for a clinical-stage biotech that must raise cash episodically. Limited leverage reduces downside bankruptcy risk, preserves optionality for partnership structuring, and supports survival through lengthy clinical timelines without heavy interest burden.
High Gross Margins And 2025 Revenue ReboundVery high gross margins indicate inherently scalable product economics or favorable licensing revenue mix if products are commercialized or partnered. The sharp 2025 revenue rebound signals potential for deal-driven income, improving the structural path to positive margins if operating costs can be managed.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow means Addex remains reliant on external financing or partner funding to advance programs. Even with improvement in 2025, continued cash consumption raises dilution and execution risk, constraining the company’s ability to self-fund trials or scale operations long-term.
Deep, Volatile Operating LossesMassive and inconsistent operating losses reflect a business still pre-commercial and R&D intensive. Volatile profitability—positive net driven by non-operating items in one year—undermines forecasting and signals that core operations are far from self-sustaining absent material partnership or licensing revenue.
Tiny Scale And Capital VolatilityExtremely small operational scale and large swings in equity/capitalization increase execution and financing risk. With only a couple employees, core capabilities depend on partnerships or outsourced R&D, and equity volatility implies recurring fundraising or accounting moves that can dilute shareholders and destabilize long-term planning.
Addex Therapeutics News
ADXN FAQ
What was Addex Therapeutics’s price range in the past 12 months?
Addex Therapeutics lowest stock price was $5.41 and its highest was $12.05 in the past 12 months.
What is Addex Therapeutics’s market cap?
Addex Therapeutics’s market cap is $6.78M.
When is Addex Therapeutics’s upcoming earnings report date?
Addex Therapeutics’s upcoming earnings report date is Jun 15, 2026 which is in 3 days.
How were Addex Therapeutics’s earnings last quarter?
Currently, no data Available
Is Addex Therapeutics overvalued?
According to Wall Street analysts Addex Therapeutics’s price is currently Overvalued.
Does Addex Therapeutics pay dividends?
Addex Therapeutics does not currently pay dividends.
What is Addex Therapeutics’s EPS estimate?
Addex Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Addex Therapeutics have?
Addex Therapeutics has 1,822,121 shares outstanding.
What happened to Addex Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Addex Therapeutics?
Currently, no hedge funds are holding shares in ADXN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Addex Therapeutics
Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their core strategy involves identifying oral small-molecule allosteric modulators for G-protein coupled receptors. The company's key programs include Dipraglurant, an investigational treatment for Parkinson's disease levodopa-induced dyskinesia and dystonia; ADX71149, which is being developed for epilepsy and other unspecified CNS conditions; and GABAB PAM, a compound aimed at treating addiction. Addex Therapeutics has established licensing and collaboration agreements with significant partners, including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002 and based in Geneva, Switzerland, the company was initially known as Addex Pharmaceuticals Ltd before officially changing its name to Addex Therapeutics Ltd in March 2012.
ADXN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted significant progress in key programs and strategic collaborations, which are positive indicators for future growth. However, the need for additional funding for unpartnered programs and stable but limited income suggest challenges in financial sustainability.View all ADXN earnings summariesTechnical Analysis
Kiora Pharmaceuticals
―
Xenetic Biosciences
―
Nucana
―
Creative Medical Technology Holdings
―
HCW Biologics
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.05% Other Institutional Investors
99.95% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---